A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorFangYi
About this trial
This study, called PERSEVERE, examines how local treatment for early breast cancer affects people's health and daily lives over time.
People who join the study will have early-stage breast cancer and receive treatment such as surgery and other therapies that are used before or after surgery. The study does not include people with late-stage (metastatic) breast cancer.
Researchers want to learn about short- and long-term side effects that can happen during or after treatment. These may include tiredness, trouble sleeping, emotional distress, pain, or changes in heart or lung function. The study also looks at how these effects impact participants' quality of life.
Participants will be asked to complete surveys about how they feel. They will also have health checks, such as heart tests, lung function tests, and blood samples. Tissue samples from surgery will also be collected.
The goal is to understand better how different people respond to breast cancer treatment and find ways to support long-term recovery.
Eligibility criteria
Qualifiers
Women aged 18 years or older
Diagnosed with stage I, II, or III invasive breast cancer confirmed by pathology or cytology
No signs of metastatic disease (cancer that has spread to other parts of the body)
Willing and able to complete health questionnaires and attend follow-up visits
Disqualifiers
Have metastatic breast cancer or local recurrence
Have already received curative treatment (surgery, chemo, etc.) for the current breast cancer before joining the study
Are currently pregnant or breastfeeding
Have a history of another cancer within the past 5 years (except for non-melanoma skin cancer or in-situ cervical cancer)
Trial design
Treatments tested in this trial
- blood sampling
Treatment groups
3,000 Participants
are divided into 1 treatment groupSponsors and collaborators
FangYi
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sponsor institution
Source ClinicalTrials.gov